Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

BACKGROUND: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (OncotypeDX,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Jahn, Beate, Rochau, Ursula, Kurzthaler, Christina, Hubalek, Michael, Miksad, Rebecca, Sroczynski, Gaby, Paulden, Mike, Bundo, Marvin, Stenehjem, David, Brixner, Diana, Krahn, Murray, Siebert, Uwe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5644100/
https://ncbi.nlm.nih.gov/pubmed/29037213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3603-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados